Table 3: Pharmacological properties of total EGCG dosages (50 to 1600mg) studied in healthy volunteers (Ullmann et al. 2003)

Parameter	Result
Relative bioavaliability	1.6% at low dose (75 mg/kg body weight); 13.9% at higher doses (250 mg/kg and 400 mg/kg body weight)
Maximum plasma concentration (C_{max})	130 to 3392 ng/ml
Time to reach C_{max} (T_{max})	60 - 115 min
AUC (0-∞)*	442 to 10,368 ng·h/ml
Apparent terminal elimination half-life ($t_{½z}$)	2.2 h after i.v. and 5 – 6 h after oral administration
Safety and tolerability	was present within a dosage of up to 1600 mg

*AUC (0-∞): Area under the concentration-time curve from 0 h to infinity